United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride tablets are indicated in the management of hypertension. it may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. prop

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

United States - English - NLM (National Library of Medicine)

greenstone llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings).

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: arrow - cabergoline is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2. after stillbirth or abortion. treatment of hyperprolactinaemic disorders: cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.

Malta - English - Medicines Authority

teva pharma b.v. (mijdrecht) industrieweg 23, p.o. box 217, 3640 ae mijdrecht, netherlands - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

United States - English - NLM (National Library of Medicine)

apotex corp. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg